A Cost Analysis of Phosphodiesterase Type 5 Inhibitors in the United States.

Behnam Nabavizadeh¹, Amanda Nguyen², Diane Li², Jeroen van Meijgaard², Benjamin N Breyer³

¹Department of Urology, University of California San Francisco, San Francisco, CA; Department of Urology, Weill Cornell Medicine, New York, NY.

²GoodRx, Santa Monica, CA.

³Department of Urology, University of California San Francisco, San Francisco, CA; Department of Biostatistics and Epidemiology, University of California San Francisco, San Francisco, CA. Electronic address: Benjamin.Breyer@ucsf.edu.

PubMed DOI

Abstract

OBJECTIVE: To perform a cost analysis of generic and brand-name Phosphodiesterase Type 5 (PDE5) inhibitors at different dosages and pharmacies across the US. METHODS: Using an all-payer retail pharmacy-claims database, we analyzed prescription drug data for three generic and six brand-name oral PDE5 inhibitors at different dosages across US chain and independent pharmacies in 2019. RESULTS: We o…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.